Table 3.
Relationship between PKM2 expression and clinicopathological features of breast cancer patients with HR-ve versus HR + ve tumors
| Parameters | HR -ve | HR + ve | ||||
|---|---|---|---|---|---|---|
| Low PKM2 | High PKM2 | p-value | Low PKM2 | High PKM2 | p-value | |
| Age (Years) | 51.88 ± 12.82 | 48.96 ± 11.78 | 0.929 | 53.08 ± 12.27 | 51.53 ± 9.54 | 0.575 |
|
Tumor grade I II III |
0 (0.0) 7 (16.7) 35 (83.3) |
0 (0.0) 2 (8.0) 23 (92.0) |
0.466 |
4 (11.1) 10 (27.8) 22 (61.1) |
3 (10.0) 14 (46.7) 13 (43.3) |
0.270 |
| Tumor volume (cm 3 ) | 47.87 ± 67.56 | 66.64 ± 125.41 | 0.428 | 24.97 ± 34.89 | 34.28 ± 48.29 | 0.368 |
|
TNM Stage I II III IV |
1 (2.5) 14 (35.0) 14 (35.0) 11 (27.5) |
2 (8.0) 4 (16.0) 10 (40.0) 9 (36.0) |
0.297 |
3 (8.3) 10 (27.8) 11 (30.6) 12 (33.3) |
0 (0.0) 8 (27.6) 9 (31.0) 12 (41.4) |
0.532 |
|
TNM I/II III/IV |
15 (37.5) 25 (62.5) |
6 (24.0) 19 (76.0) |
0.290 |
13 (36.1) 23 (63.9) |
8 (27.6) 21 (72.4) |
0.595 |
|
T stage T1 T2 T3 T4 |
2 (4.8) 22 (52.4) 13 (31.0) 5 (11.9) |
3 (12.0) 11 (44.0) 9 (36.0) 2 (8.0) |
0.640 |
5 (13.9) 19 (52.8) 9 (25.0) 3 (8.3) |
0 (0.0) 18 (60.0) 10 (33.3) 2 (6.7) |
0.197 |
|
pT T1/T2 T3/T4 |
24 (57.1) 18 (42.9) |
14 (56.0) 11 (44.0) |
1.000 |
24 (66.7) 12 (33.3) |
18 (60.0) 12 (40.0) |
0.615 |
|
pN stage N0 N1 N2 N3 |
11 (28.2) 13 (33.3) 6 (15.4) 9 (23.1) |
7 (28.0) 2 (8.0) 6 (24.0) 10 (40.0) |
0.093 |
12 (34.3) 6 (17.1) 7 (20.0) 10 (28.6) |
8 (27.6) 9 (31.0) 6 (20.7) 6 (20.7) |
0.602 |
|
M stage M0 M1 |
29 (72.5) 11 (27.5) |
16 (64.0) 9 (36.0) |
0.583 |
24 (66.7) 12 (33.3) |
17 (58.6) 12 (41.4) |
0.607 |
|
Axillary lymph nodes metastasis Negative Positive |
11 (27.5) 29 (72.5) |
7 (28.0) 18 (72.0) |
1.000 |
12 (33.3) 24 (66.7) |
9 (30.0) 21 (70.0) |
0.797 |
|
Lymphatic/vascular invasion Negative Positive |
15 (38.5) 24 (61.5) |
6 (26.1) 17 (73.9) |
0.409 |
16 (45.7) 19 (54.3) |
7 (23.3) 23 (76.7) |
0.073 |
|
HER2 status Negative Positive |
11 (26.2) 31 (73.2) |
17 (68.0) 8 (32.0) |
0.001 |
7 (19.4) 29 (80.6) |
24 (80.0) 6 (20.0) |
< 0.001 |
|
DCIS Absent Present |
8 (19.0) 34 (81.0) |
10 (43.5) 13 (56.5) |
0.046 |
7 (19.4) 29 (80.6) |
3 (10.0) 27 (90.0) |
0.327 |
|
Family History No Yes |
17 (70.8) 7 (29.2) |
15 (68.2) 7 (31.8) |
1.000 |
25 (78.1) 7 (21.9) |
26 (89.7) 3 (10.3) |
0.307 |
|
Ki-67 Low High |
19 (45.2) 23 (54.8) |
11 (44.0) 14 (56.0) |
1.000 |
24 (66.7) 12 (33.3) |
24 (80.0) 6 (20.0) |
0.275 |
|
SP Low High |
24 (57.1) 18 (42.9) |
17 (68.0) 8 (32.0) |
0.444 |
26 (72.2) 10 (27.8) |
12 (40.0) 18 (60.0) |
0.012 |
|
NK1R Low High |
26 (61.9) 16 (38.1) |
12 (48.0) 13 (52.0) |
0.314 |
24 (66.7) 12 (33.3) |
21 (70.0) 9 (30.0) |
0.797 |
HR: hormone receptor, HER2: human epidermal growth factor receptor 2, DCIS: ductal carcinoma in situ, SP: substance P, NK1R: neurokinin 1 receptor, PKM2: pyruvate kinase M2